Allogene Therapeutics Inc., a biotechnology company specializing in allogeneic CAR T products for cancer and autoimmune diseases, is set to participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10. The company will join the event to discuss its innovative approaches and developments in the field.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.